Donor Lymphocyte Infusion (Northwell Health)

Donor Lymphocyte Infusion (DLI) is an adoptive cellular immunotherapy used primarily to treat or prevent relapse after allogeneic hematopoietic stem cell transplantation (HSCT). In the specific "Two-Step" haploidentical transplant protocol developed by Northwell Health (based on methodology from Thomas Jefferson University), DLI is administered as the first step to provide early immune reconstitution and anti-leukemic activity through a graft-versus-tumor (GVT) effect. This is followed by the administration of cyclophosphamide to induce immune tolerance by selectively depleting alloreactive T-cells, and subsequently, the infusion of CD34+ selected donor stem cells. This regimen is designed for children and young adults with high-risk hematologic malignancies, including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic myeloid leukemia (CML), and various lymphomas, who lack a suitably matched related or unrelated donor.

Other names

DLIDonor T-cell infusion